MAPT and Alzheimer disease: In a validation cohort of autopsy-confirmed AD and control cases without dementia who contributed parietal cortex tissue samples (cohort 2: (ref. 29) n = 8), the tau-FRET signal was again ~300-fold higher in AD versus control tissues (P = 0.0286; Fig. 1d).